Sponsored by
A large molecular analysis of 3,106 glioblastoma (GBM) tumor samples - including 571 from patients treated with bevacizumab (Avastin) - found that CDK4 amplification is a potential biomarker to identify patients who may derive prolonged benefit from bevacizumab. For more information on bevacizumab, you can visit our website!